New Drug for Chronic Migraine: FDA Approves Atogepant to Prevent Chronic Migraine in Adults

In the Press release published by AbbVie on April 17, 2023, it was reported that the FDA approved the expansion of the indication of atogepant (Qulipta, AbbVie) for the preventive treatment of migraine in adults. After this event, atogepant was introduced with the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine.

Atogepant was approved in September 2021 as a preventive treatment for episodic migraine. Atogepant is available as a single daily dose for the preventive treatment of episodic migraine: 10, 30, and 60 mg. Only 60 mg of the drug is indicated for the preventive treatment of chronic migraine. It can be taken with or without food. The most common side effects of Atogepant include constipation, nausea, and tiredness/drowsiness.